ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

ACRS Aclaris Therapeutics Inc

1,38
0,07 (5,34%)
04 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Aclaris Therapeutics Inc ACRS NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,07 5,34% 1,38 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
1,31 1,31 1,40 1,36 1,31
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
30.4.202413:00GLOBEAclaris Therapeutics to Announce First Quarter 2024..
23.4.202414:00PRNUSFlare Therapeutics Appoints Douglas Manion, M.D., FRCP (C)..
05.3.202423:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.3.202423:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.3.202423:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.2.202413:30EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27.2.202413:14EDGAR2Form 8-K - Current report
27.2.202413:00GLOBEAclaris Therapeutics Reports Fourth Quarter and Full Year..
15.2.202402:32EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14.2.202420:06EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13.2.202420:24EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06.2.202401:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.2.202401:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.2.202401:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.2.202401:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.2.202422:31EDGAR2Form 8-K/A - Current report: [Amend]
05.2.202422:30EDGAR2Form 8-K - Current report
19.1.202413:30EDGAR2Form 8-K - Current report
16.1.202413:00GLOBEAclaris Therapeutics Announces Leadership Changes and..
10.1.202413:00GLOBEAclaris Therapeutics Announces Top-line Results from 4-Week..
03.1.202422:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.1.202422:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19.12.202322:15EDGAR2Form 8-K - Current report
19.12.202322:01GLOBEAclaris Therapeutics Provides Corporate Update
05.12.202322:01GLOBEAclaris Therapeutics Announces Patent License Agreement with..
13.11.202313:42EDGAR2Form 8-K - Current report
13.11.202313:00GLOBEAclaris Therapeutics Announces Top-line Results from 12-Week..
06.11.202313:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06.11.202313:15EDGAR2Form 8-K - Current report
06.11.202313:00GLOBEAclaris Therapeutics Reports Third Quarter 2023 Financial..
25.10.202322:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.10.202322:06EDGAR2Form 144 - Report of proposed sale of securities
03.10.202313:00GLOBEAclaris Therapeutics Completes Enrollment in Phase 2b Study..
20.9.202313:00GLOBEAclaris Therapeutics to Participate in the 2023 Cantor..
18.9.202314:00EDGAR2Form 8-K - Current report
18.9.202313:00GLOBEAclaris Therapeutics Announces Positive Results from Phase 1..
07.9.202322:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.9.202323:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28.8.202322:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.8.202322:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.8.202322:20EDGAR2Form 144 - Report of proposed sale of securities
07.8.202313:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07.8.202313:15EDGAR2Form 8-K - Current report
07.8.202313:00GLOBEAclaris Therapeutics Reports Second Quarter 2023 Financial..
03.8.202322:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.7.202322:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.6.202313:01GLOBEAclaris Therapeutics Completes Enrollment in Phase 2b Study..
02.6.202313:00GLOBEAclaris Therapeutics to Participate in Two June Healthcare..
08.5.202313:00GLOBEAclaris Therapeutics Reports First Quarter 2023 Financial..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock